PRNewsWire
10 Aug 2026, 06:32 UTC · 1h ago
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
PRNewsWire
10 Aug 2026, 06:32 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Sobi and Innate Pharma have entered a strategic partnership to advance the Phase 3 TELLOMAK-3 study for lacutamab in cutaneous T-cell lymphoma (CTCL). — Initiating a pivotal Phase 3 trial is a critical de-risking step toward commercialization for a first-in-class therapy.
+0.60Under the agreement, Sobi will pay Innate an upfront payment of USD 75 million, with potential future milestones reaching up to USD 505 million. — Significant guaranteed cash inflow and high contingent payments provide a substantial valuation floor and liquidity boost for Innate Pharma.
+0.50Sobi will receive exclusive global commercialization rights upon potential accelerated approval of lacutamab. — Secures a potential new revenue stream and expands Sobi's rare disease portfolio with a therapy having FDA Fast Track and EMA PRIME designations.
+0.40Continue reading
6 related stories
Top 2 movers · tap to explore
Innate Pharma is eligible to receive tiered double-digit royalties on future net sales of lacutamab. — Provides Innate with long-term upside potential based on the commercial success of the drug without bearing the full commercialization cost.
+0.30Which stocks this story touches
Secured a strategic partnership including a $75 million upfront payment and potential milestones totaling over $500 million.
Entered a strategic partnership to license lacutamab and strengthen its rare disease portfolio.
Mentioned only as a collaborator on a different project (monalizumab) without any new material updates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
1d ago
